Clinical Trial Update: Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

View source ↗

Summary

A clinical trial evaluating a taxane-based combined targeted therapy for low-risk HER2-positive, lymph node-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Shu Wang | Conditions: HER2-positive Breast Cancer | Status: RECRUITING